The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial.
Human reproduction (Oxford, England) • Vol. 25, Issue 4 • 2010
Quinagolide--a valuable treatment option for hyperprolactinaemia.
European journal of endocrinology • Vol. 154, Issue 2 • 2006
The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Clinical endocrinology • Vol. 53, Issue 1 • 2000
Quinagolide in the management of prolactinoma.
Pituitary • Vol. 3, Issue 4 • 2000
